Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Filings indexed 680 across all filing types
Latest filing 2023-08-07 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated August 7, 2023, announcing the Q1FY24 financial results of Gland Pharma Limited. It includes detailed financial data such as revenue, profit, margins, segment performance, R&D expenditure, and capex for the quarter ended June 30, 2023. The document also mentions an upcoming earnings call to discuss these results. The presence of comprehensive quarterly financial data and analysis indicates this is a quarterly financial report rather than a brief earnings highlight or an announcement of a report. It is not a full annual report (10-K) but a quarterly report with substantive financial information. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2024
2023-08-07 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation on Q1FY24 Financial Results' and is dated August 7, 2023. It contains detailed financial data for the quarter Q1 FY24, including revenue, EBITDA, PAT, segment performance, and acquisition impact. The document is explicitly described as an 'Investor Presentation' and includes forward-looking statements, financial highlights, and operational updates. It is not a full annual or quarterly report but a presentation aimed at investors summarizing quarterly financial results and business highlights. Therefore, the document fits the category of an Investor Presentation (IP). The document length is about 15,000 characters, indicating it is a full presentation rather than a brief announcement or certification.
2023-08-07 English
Change in Management
Interim / Quarterly Report Classification · 95% confidence The document is dated August 7, 2023, and is addressed to stock exchanges with a subject line indicating the outcome of a Board Meeting. It includes approval of unaudited financial results for the quarter ended June 30, 2023, along with a Limited Review Report pursuant to SEBI regulations. The document also announces a change in senior management personnel and amendments to a policy. The presence of unaudited quarterly financial results and a Limited Review Report indicates this is a quarterly financial report. The document contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-08-07 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is dated August 7, 2023, and is addressed to stock exchanges with a subject line indicating the outcome of a Board Meeting. It includes approval of unaudited financial results for the quarter ended June 30, 2023, along with a Limited Review Report pursuant to SEBI regulations. The document also announces a change in senior management personnel and amendments to a policy. The presence of unaudited financial results and a Limited Review Report for a quarter strongly indicates this is a quarterly interim financial report. The document contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-08-07 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Gland Pharma Limited dated August 7, 2023, reporting the outcome of a Board Meeting. It includes approval of unaudited financial results for the quarter ended June 30, 2023, along with a Limited Review Report by the auditors. The document also announces a change in senior management personnel and amendments to the company's policy on materiality. The presence of unaudited financial results and a Limited Review Report for a quarter indicates this is a quarterly financial report. The document contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-08-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about an upcoming Earnings Conference Call scheduled for August 7, 2023, to discuss the company's financial performance for the quarter ended June 30, 2023. It includes details about the call, dial-in information, and contact details. There is no actual financial data or results presented in this document, only an announcement of the call. According to the classification rules, announcements about earnings calls are classified as Call Transcript (CT) only if they contain the full transcript. Since this document is only an announcement of the call and not the transcript itself, it does not fit CT. It is also not an Earnings Release (ER) because it does not contain financial highlights or results. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call event.
2023-07-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.